{"product_id":"biolegend-108112","title":"Biolegend, 108112, APC anti-mouse Ly-6A\/E (Sca-1) Antibody, 100μg","description":"\u003cp\u003eLy-6A\/E, also known as Sca-1, is an 18 kD member of the Ly-6 multigene family. Ly6A\/E is a glycosylphosphatidylinositol (GPI)-linked protein expressed on hematopoietic stem cells. In mice expressing the Ly-6.2 haplotype (e.g., AKR, C57BL, C57BR, DBA\/2, SJL, SWR, and 129), Ly-6A\/E is also expressed on peripheral B lymphocytes and thymic and peripheral T lymphocytes. Strains expressing the Ly-6.1 haplotype (e.g., BALB\/c, CBA, C3H\/He, DBA\/1, and NZB) have low Ly-6A\/E expression on resting peripheral lymphocytes. The expression of Ly-6A\/E on lymphocytes is upregulated upon activation from both Ly6.1 and Ly6.2 haplotype mice. Ly-6A\/E is thought to be involved in the regulation of both T and B cell responses.\u003cbr\u003e\n100μg\u003cbr\u003e\nVerified Reactivity: Mouse\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Rat\u003cbr\u003e\nImmunogen: IL-2-dependent mouse T-cell line (CTL-L)\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.\u003cbr\u003e\nConcentration: 0.2 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: FC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.\u003cbr\u003e\nExcitation Laser: Red Laser (633 nm)\u003cbr\u003e\nApplication Notes: The D7 antibody has been reported to induce T cell activation and inhibit TCR-induced IL-2 production. Additional reported applications (for the relevant formats) include: Western blotting1,2, immunoprecipitation1, in vitro lymphocyte activation3-6, induction of redirected lysis7, induction of T cell inhibitory signalling8, immunofluorescence9, and immunohistochemical staining of acetone-fixed frozen sections13 and Bouin-fixed, paraffin-embedded samples9. The two Sca-1 recognizing clones D7 and E13-161.7 have been shown to bind distinct epitopes due to the inability of D7 to block the binding of E13-161.7.14\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Ortega G, et al. 1986. J. Immunol. 137:3240. (WB, IP) Palfree RGE, et al. 1986. Immunogenetics 23:197. (WB) Codias EK, et al. 1990. J. Immunol. 144:2197. Malek TR, et al. 1986. J. Exp. Med. 164:709. Codias EK, et al. 1990. J. Immunol. 145:1407. Ivanov V, et al. 1994. J. Immunol. 153:2394. Karlhofer FM, et al. 1991. J. Immunol. 146:3662. Fleming T, et al. 1994. J. Immunol. 153:1955. van Bragt MPA, et al. 2005. Biol. Reprod. 73:634. (IF, IHC) Umland O, et al. 2007. J. Immunol. 178:4147. Cridland SO, et al. 2009. Blood Cell. Mol. Dis. 45:149. (FC) PubMed Pronk CJ, et al. 2011. J. Exp Med. PubMed English A, et al. 2000. J. Immunol. 165:3763. (IHC) Bamezai A and Rock KL. 1995. Proc. Natl. Acad. Sci. USA 92:4294. Wiesner DL, et al. 2015. PLoS Pathog. 11:1004701. PubMed\u003cbr\u003e\nProduct Citations: Feng X, et al. 2023. Nat Commun. 14:3208. PubMed Alam A, et al. 2022. Cancer Cell. 40:153. PubMed Leinroth AP, et al. 2022. Cell Rep. 39:110785. PubMed Moiseeva V, et al. 2023. Nature. 613:169. PubMed Tang Y, et al. 2022. Dev Cell. 57:480. PubMed Li DD, et al. 2022. Cell Host Microbe. 30:530. PubMed Mikami Y, et al. 2021. Immunity. 54(3):514-525.e6. PubMed Umland O, et al. 2007. J Immunol . 178:4147. PubMed Ju W, et al. 2020. J Biomed Sci. 27:91. PubMed Viny AD, et al. 2019. Cell Stem Cell. 25:682. PubMed Shi Y, et al. 2020. Med Sci Monit. 26:e923328. PubMed Bo Yu et al. 2018. Cell stem cell. 23(2):193-209 . PubMed Philpott J, et al. 2022. Immunohorizons. 6:366. PubMed Larouche JA, et al. 2021. eLife. 0.416666666666667. PubMed Nguyen N, et al. 2022. iScience. 25:103679. PubMed Hinterbrandner M, et al. 2021. JCI Insight. 6:e151797. PubMed Liu X, et al. 2021. eLife. 0.416666666666667. PubMed Yamamoto K, et al. 2021. Cell Reports. 36(8):109576. PubMed Mann M, et al. 2018. Cell Rep. 25:2992. PubMed Yin N et al. 2019. Cancer Cell. 36(2):156-167 . PubMed Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed Fujino T, et al. 2021. Nat Commun. 12:1826. PubMed Endo Y, et al. 2020. FASEB J. 34:16086. PubMed Vannini N, et al. 2019. Cell Stem Cell. 24:405. PubMed De S, et al. 2018. Development. 145. PubMed Wiesner D, et al. 2015. PLoS Pathog. 11:1004701. PubMed Kunimoto H, et al. 2018. Cancer Cell. 33:44. PubMed Hillel–Karniel C, et al. 2020. Cell Reports. 30(3):807-819.e4.. PubMed Shcherbina A, et al. 2020. Cell Rep. 32:107964. PubMed Derecka M, et al. 2020. Nat Immunol. 261:21. PubMed Jungwirth N et al. 2018. Journal of molecular neuroscience : MN. 65(1):60-73 . PubMed Hou M, et al. 2020. Stem Cell Res Ther. 11:55. PubMed Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed Ferreirinha P, et al. 2022. Development. 149: . PubMed Hepler C et al. 2018. eLife. 7 pii: e39636. PubMed Ikram M, et al. 2018. Oncotarget. 9:2058. PubMed Tavakol DN, et al. 2021. Curr Protoc. 1:e275. PubMed Mizbani A, et al. 2016. Development. 143: 4137 - 4148. PubMed Ding P, et al. 2022. Bone Res. 10:42. PubMed Gentek R, et al. 2018. Immunity. 48:1160. PubMed Goldstein JM et al. 2019. Cell reports. 27(4):1254-1264 . PubMed Luo H, et al. 2020. Cancer Cell. 36(6):645-659.e8.. PubMed Keerthivasan S, et al. 2021. Immunity. 54(7):1511-1526.e8. PubMed Bastianutto C, et al. 2007. Cancer Res. 67:10112. PubMed Glotzbach J, et al. 2011. PLoS One. 6:e21211. PubMed Luo H, et al. 2022. Mol Cell. 82:833. PubMed Wolock SL, et al. 2019. Cell Rep. 28:302. PubMed Singhal P, et al. 2016. Proc Natl Acad Sci U S A. 113: 122 - 127. PubMed Markworth JF, et al. 2020. JCI Insight. 5:00. PubMed Rodríguez L, et al. 2021. Biomolecules. 11: . PubMed Wong J, et al. 2016. Sci Signal. 9: ra103. PubMed Vannini N, et al. 2016. Nat Commun. 7:13125. PubMed Liu Q, et al. 2016. Cell Death Dis. 1.93125. PubMed Zhang Y, et al. 2008. Mol Cell Biol. 28:1688. PubMed Thomson CA, et al. 2018. J Immunol. 201:215. PubMed Cohen I et al. 2018. Cell stem cell. 22(5):726-739 . PubMed Vogiatzi A, et al. 2021. Mol Cell Biol. 41:e0014921. PubMed\u003cbr\u003e\nRRID: AB_313348 (BioLegend Cat. No. 108111) AB_313349 (BioLegend Cat. No. 108112)\u003cbr\u003e\nStructure: Ly-6 multigene family, 18 kD\u003cbr\u003e\nDistribution: Hematopoietic stem cells, activated T cells and B cells, subset of resting B cells and T cells\u003cbr\u003e\nFunction: Regulates B and T cell responses\u003cbr\u003e\nCell Type: B cells, Hematopoietic stem and progenitors, Mesenchymal Stem Cells, T cells\u003cbr\u003e\nBiology Area: Immunology, Stem Cells\u003cbr\u003e\nAntigen References: 1. Rock KL, et al. 1989. Immunol. Rev. 111:195. 2. Morrison SJ, et al. 1994. Immunity 1:661. 3. Spangrude GJ, et al. 1988. J. Immunol. 141:3697. 4. Malek T, et al. 1986. J. Exp. Med. 164:709.\u003cbr\u003e\nGene ID: 110454\u003cbr\u003e\nUniProt: View information about Ly-6A\/E on UniProt.org\u003cbr\u003e\nClone: D7\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: Sca-1\u003cbr\u003e\nIsotype: Rat IgG2a, κ\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46863002304681,"sku":"108112","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/ar\/products\/biolegend-108112","provider":"Iright","version":"1.0","type":"link"}